Brief: Vertex Pharmaceuticals VERTEX PHARMACEUTICALS Q3 ADJUSTED EPS USD 4.8 VS. IBES ESTIMATE USD 4.56
03/11/2025 21:02
Nov 03 (Reuters) - Vertex Pharmaceuticals Q3 adjusted net income USD 1,082.9 million vs. IBES estimate USD 1,190 million. VERTEX PHARMACEUTICALS Q3 REVENUE USD 3,080 MILLION VS. IBES ESTIMATE USD 3,053 MILLION VERTEX PHARMACEUTICALS Q3 EPS USD 4.2 VERTEX PHARMACEUTICALS OUTLOOK FY REVENUE USD 11,900-12,000 MILLION
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria